{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:24:51Z","timestamp":1787765091497,"version":"build-2784847793"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Sunitinib remains the first-line treatment for favorable risk metastatic clear cell renal cell cancer (mccRCC). It was conventionally given in the 4\/2 schedule; however, toxicity necessitated trying the 2\/1 regimen. Regional variations in treatment response and toxicity are known, and there is no data from the Indian subcontinent about the outcomes of the alternative dosing schedule.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Clinical records of all consecutive adult patients who received sunitinib as first-line therapy for histologically proven mccRCC following cytoreductive nephrectomy from 2010\u20132018 were reviewed. The primary objective was to determine the progression-free survival (PFS), and the secondary objectives were to evaluate the response rate (objective response rate and clinical benefit rate), toxicity, and overall survival. A list of variables having a biologically plausible association with outcome was drawn and multivariate inverse probability treatment weights (IPTW) analysis was done to determine the absolute effect size of dosing schedules on PFS in terms of \u201caverage treatment effect on the treated\u201d and \u201cpotential outcome mean.\u201d<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>We found 2\/1 schedule to be independently associated with higher PFS on IPTW analysis such that if every patient in the subpopulation received sunitinib by the 2\/1 schedule, the average time to progression was estimated to be higher by 6.1 months than the 4\/2 schedule. We also found 2\/1 group to have a lower incidence than the 4\/2 group for nearly all \u2265 grade 3 adverse effects. Other secondary outcomes were comparable between both treatment groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Sunitinib should be given via the 2\/1 schedule in Indian patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijc.ijc_1284_20","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T23:00:09Z","timestamp":1704841209000},"page":"493-500","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["2\/1 dose schedule of sunitinib is superior than the 4\/2 regimen for the first-line therapy of clear cell metastatic renal cell carcinoma \u2013 An Indian experience"],"prefix":"10.4103","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3223-8155","authenticated-orcid":false,"given":"Jiten","family":"Jaipuria","sequence":"first","affiliation":[{"name":"Amity Centre for Cancer Epidemiology and Cancer Research, Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1325-6377","authenticated-orcid":false,"given":"Ankita","family":"Jain","sequence":"additional","affiliation":[{"name":"Uro-Oncology Division, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, Sector \u2013 5, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-0635","authenticated-orcid":false,"given":"Shashikant","family":"Gupta","sequence":"additional","affiliation":[{"name":"Uro-Oncology Division, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, Sector \u2013 5, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6630-3130","authenticated-orcid":false,"given":"Nripesh","family":"Sadasukhi","sequence":"additional","affiliation":[{"name":"Uro-Oncology Division, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, Sector \u2013 5, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5747-1933","authenticated-orcid":false,"given":"Priyatham","family":"Kasaraneni","sequence":"additional","affiliation":[{"name":"Uro-Oncology Division, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, Sector \u2013 5, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8180-1891","authenticated-orcid":false,"given":"Amitabh","family":"Singh","sequence":"additional","affiliation":[{"name":"Uro-Oncology Division, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, Sector \u2013 5, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5962-5879","authenticated-orcid":false,"given":"Kush","family":"Gupta","sequence":"additional","affiliation":[{"name":"Catalyst Clinical Services Pvt. Ltd., New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2127-5700","authenticated-orcid":false,"given":"Girish","family":"Sharma","sequence":"additional","affiliation":[{"name":"Amity Centre for Cancer Epidemiology and Cancer Research, Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9149-6969","authenticated-orcid":false,"given":"Vineet","family":"Talwar","sequence":"additional","affiliation":[{"name":"Medical Oncology Division, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, Sector \u2013 5, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-2372","authenticated-orcid":false,"given":"Sudhir Kumar","family":"Rawal","sequence":"additional","affiliation":[{"name":"Uro-Oncology Division, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, Sector \u2013 5, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,1,9]]},"reference":[{"key":"R2-20240828","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4103\/ijmpo.ijmpo_126_16","article-title":"Renal cell cancer: Clinicopathological profile and survival outcomes","volume":"39","author":"Tiwari","year":"2018","journal-title":"Indian J Medical Paediatr Oncol"},{"key":"R4-20240828","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.7150\/jca.25693","article-title":"Improved long-term clinical outcomes and safety profile of sunitinib dosing schedule with 4\/2 switched to 2\/1 in patients with metastatic renal cell carcinoma","volume":"9","author":"Zhang","year":"2018","journal-title":"J Cancer"},{"key":"R5-20240828","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4103\/0019-509X.180844","article-title":"Sunitinib in metastatic renal cell carcinoma: Experience from single center study, efficacy and safety","volume":"53","author":"Patel","year":"2016","journal-title":"Indian J Cancer"},{"key":"R6-20240828","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1080\/0284186X.2016.1265666","article-title":"Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: A meta-analysis","volume":"56","author":"Liu","year":"2017","journal-title":"Acta Oncol"},{"key":"R7-20240828","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00280-007-0498-4","article-title":"A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period","volume":"61","author":"Britten","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"R8-20240828","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/jjco\/hyq073","article-title":"The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: High incidence of toxicity leads to frequent dose reduction","volume":"40","author":"Yoo","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"R9-20240828","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","article-title":"Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma","volume":"17","author":"Motzer","year":"1999","journal-title":"J Clin Oncol"},{"key":"R10-20240828","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: A population-based study","volume":"14","author":"Heng","year":"2013","journal-title":"Lancet Oncol"},{"key":"R11-20240828","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.eururo.2016.07.005","article-title":"The role of cytoreductive nephrectomy: European association of urology recommendations in 2016","volume":"70","author":"Bex","year":"2016","journal-title":"Eur Urol"},{"key":"R12-20240828","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"R13-20240828","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"R16-20240828","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/1475-6773.00165","article-title":"Improved comorbidity adjustment for predicting mortality in Medicare populations","volume":"38","author":"Schneeweiss","year":"2003","journal-title":"Health Serv Res"},{"key":"R17-20240828","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","article-title":"Bias reduction of maximum likelihood estimates","volume":"1","author":"Firth","year":"1993","journal-title":"Biometrika"},{"key":"R19-20240828","doi-asserted-by":"crossref","first-page":"e000891","DOI":"10.1136\/jitc-2020-000891","article-title":"Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial","volume":"8","author":"Motzer","year":"2020","journal-title":"J Immunother Cancer"},{"key":"R20-20240828","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.628","article-title":"Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: Analysis of the STAR TOR registry","volume":"38","author":"Moran","year":"2020","journal-title":"J Clin Oncol"},{"key":"R21-20240828","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.2217\/fon-2018-0858","article-title":"Safety and effectiveness of classical and alternative sunitinib dosing schedules for metastatic renal cell carcinoma: A meta-analysis","volume":"15","author":"Abogunrin","year":"2019","journal-title":"Future Oncol"},{"key":"R22-20240828","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3389\/fonc.2020.00313","article-title":"A 2\/1 Sunitinib dosing schedule provides superior antitumor effectiveness and less toxicity than a 4\/2 schedule for metastatic renal cell carcinoma: A systematic review and meta-analysis","volume":"10","author":"Deng","year":"2020","journal-title":"Front Oncol"},{"key":"R23-20240828","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1093\/annonc\/mdv357","article-title":"RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial","volume":"26","author":"Lee","year":"2015","journal-title":"Ann Oncol"},{"key":"R24-20240828","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s12032-018-1195-3","article-title":"Significance of introduction of alternative dosing schedule for sunitinib during first-line treatment of patients with metastatic renal cell carcinoma","volume":"35","author":"Miyake","year":"2018","journal-title":"Med Oncol"},{"key":"R25-20240828","doi-asserted-by":"crossref","first-page":"268.e9","DOI":"10.1016\/j.urolonc.2015.03.008","article-title":"Sunitinib dosing schedule 2\/1 improves tolerability, efficacy, and health-related quality of life in Chinese patients with metastatic renal cell carcinoma","volume":"33","author":"Pan","year":"2015","journal-title":"Urol Oncol"},{"key":"R26-20240828","doi-asserted-by":"crossref","first-page":"e455","DOI":"10.1016\/j.clgc.2016.10.010","article-title":"Sunitinib 4\/2 Versus 2\/1 schedule for patients with metastatic renal cell carcinoma: Tertiary care hospital experience","volume":"15","author":"Ezz El Din","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"R27-20240828","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1016\/j.clgc.2017.01.016","article-title":"Outcomes and drug costs of sunitinib regimens for metastatic renal cell carcinoma: A provincial population-based study","volume":"15","author":"Suo","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"R28-20240828","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/jjco\/hyt232","article-title":"Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off","volume":"44","author":"Kondo","year":"2014","journal-title":"Jpn J Clin Oncol"},{"key":"R29-20240828","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1442-2042.2012.03204.x","article-title":"Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: A single-center experience with 31 patients","volume":"20","author":"Neri","year":"2013","journal-title":"Int J Urol"},{"key":"R30-20240828","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1093\/annonc\/mdv589","article-title":"Sunitinib administered on 2\/1 schedule in patients with metastatic renal cell carcinoma: The RAINBOW analysis","volume":"27","author":"Bracarda","year":"2016","journal-title":"Ann Oncol"},{"issue":"Suppl 15","key":"R31-20240828","doi-asserted-by":"crossref","first-page":"e16546","DOI":"10.1200\/JCO.2018.36.15_suppl.e16546","article-title":"Real world experience with nivolumab in Indian patients with metastatic renal cell carcinoma: A single centre experience","volume":"36","author":"Rauthan","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.IJC_1284_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:01:28Z","timestamp":1787763688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.IJC_1284_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijc.ijc_1284_20","relation":{},"ISSN":["0019-509X","1998-4774"],"issn-type":[{"value":"0019-509X","type":"print"},{"value":"1998-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"2020-11-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}